Topics

Glioblastoma | Treatment | Targeted therapy | Nivolumab

Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Nivolumab

Sloan AE, Winter K, Gilbert MR, Aldape K, Choi S, Wen PY, Butowski N, Iwamoto FM, Raval RR, Voloschin AD, Kamiya-Matsuoka C, Won M, Mehta MP.
NRG-BN002: Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients with Newly Diagnosed GBM.
Neuro Oncol. 2024 Jun 14:noae058. doi: 10.1093/neuonc/noae058. PMID: 38874333. Interventional study˰ ˍ

Skadborg SK, Maarup S, Draghi A, Borch A, Hendriksen S, Mundt F, Pedersen V, Mann M, Christensen IJ, Skjøth-Rasmussen J, Yde CW, Kristensen BW, Skovgaard Poulsen H, Hasselbalch B, Svane IM, Lassen U, Hadrup SR.
Nivolumab reaches brain lesions in patients with recurrent glioblastoma and induces T-cell activity and upregulation of checkpoint pathways.
Cancer Immunol Res. 2024 Jun 18. doi: 10.1158/2326-6066.CIR-23-0959. PMID: 38885356. Observational study. ˍ

Mitchell M, Restrepo-Orozco A, Verhey LH, Vitaz T.
Long-term survival in a patient with Li-Fraumeni syndrome-associated giant cell glioblastoma treated with nivolumab: illustrative case.
J Neurosurg Case Lessons. 2024 Nov 25;8(22):CASE24539. doi: 10.3171/CASE24539. PMID: 39586078. Case report. ˍ

Ipilumab, Nivolumab, Relatlimab

Long GV, Shklovskaya E, Satgunaseelan L, Mao Y, da Silva IP, Perry KA, Diefenbach RJ, Gide TN, Shivalingam B, Buckland ME, Gonzalez M, Caixeiro N, Vergara IA, Bai X, Rawson RV, Hsiao E, Palendira U, Phan TG, Menzies AM, Carlino MS, Quek C, Grimmond SM, Vissers JHA, Yeo D, Rasko JEJ, Khasraw M, Neyns B, Reardon DA, Ashley DM, Wheeler H, Back M, Scolyer RA, Drummond J, Wilmott JS, Rizos H.
Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.
Nat Med. 2025 Feb 27. doi: 10.1038/s41591-025-03512-1. PMID: 40016450. Case report. ˍ

Wen PY, Manzanera A, Duault C, Gonzalez-Kozlova E, Lopez L, Grossman SA, Ye X, Fisher J, Lee I, Walbert T, Snyder J, Brem S, Desai A, Bagley SJ, Kakani C, Strowd R, Tatter S, Laxton A, Lesser G, Amankulor N, Lieberman F, Drappatz J, Mantica M, Triggs D, Haymaker C, Wistuba II, Al-Atrash G, Mendoza Perez J, Futreal A, Little LD, Islam MDH, Duose D, Jiang P, Reuben A, Lawler SE, Pichavant M, Gentles A, Bendall S, Kong A, Camacho C, Del Valle D, Kim-Schulze S, Gnjatic S, Sharon E, Nowicki MO, Peruzzi P, Lane D, Aguilar-Cordova E, Aguilar LK, Nichols G, Dwyer J, Tak PP, Maecker H, Barone F, Chiocca EA.
A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma.
Neuro Oncol. 2025 Mar 22:noaf079. doi: 10.1093/neuonc/noaf079. PMID: 40120123. Interventional study˰ ˍ